title: Therapeutic effect of secretin in patients with jaundice; double-blind placebo-controlled multicentric trial.
abstract: Secretin, a gastrointestinal hormone, has been shown to have a potent choleretic effect. Having already obtained some beneficial effects with secretin in patients with intrahepatic cholestasis, we sought to confirm its effects in a double-blind placebo-controlled study in patients with mild jaundice after acute or during chronic hepatitis, where total bilirubin level was in excess of 4.0 mg/dl for 3 days or more. Patients with primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and familiar hyperbilirubinemia were excluded from the study. Ninety-three patients were included in this analysis, but the final evaluation covered 69 of them. No statistically significant differences were found in the reduction of serum bilirubin levels between secretin and placebo groups. As a number of patients with liver cirrhosis had been included, the subjects were subdivided into one group with cholestasis in hepatitis and one with liver cirrhosis. In the subgroup of cirrhotic patients who received secretin, serum levels of AST were significantly increased compared with the placebo group. However, since the choleretic effect of secretin is unique, further studies seem to be warranted.
authors.affiliation: First Department of Internal Medicine, Yamaguchi University School of Medicine, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Fukumoto
authors.forename: K
authors.initials: K
authors.lastname: Okita
authors.forename: T
authors.initials: T
authors.lastname: Kodama
authors.forename: S
authors.initials: S
authors.lastname: Matsuda
authors.forename: S
authors.initials: S
authors.lastname: Kawamura
authors.forename: K
authors.initials: K
authors.lastname: Harima
authors.forename: Y
authors.initials: Y
authors.lastname: Harada
authors.forename: K
authors.initials: K
authors.lastname: Kawaguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Iida
authors.forename: T
authors.initials: T
authors.lastname: Konishi
authors.forename: K
authors.initials: K
authors.lastname: Andoh
authors.forename: H
authors.initials: H
authors.lastname: Tanaka
authors.forename: T
authors.initials: T
authors.lastname: Hanta
authors.forename: T
authors.initials: T
authors.lastname: Sekitani
authors.forename: T
authors.initials: T
authors.lastname: Takenami
authors.forename: T
authors.initials: T
authors.lastname: Yamasaki
authors.forename: S
authors.initials: S
authors.lastname: Yamashita
authors.forename: H
authors.initials: H
authors.lastname: Fujimura
authors.forename: M
authors.initials: M
authors.lastname: Shimada
authors.forename: M
authors.initials: M
authors.lastname: Kohzu
authors.forename: K
authors.initials: K
authors.lastname: Shigeta
authors.forename: H
authors.initials: H
authors.lastname: Shirasawa
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001663:Bilirubin / Q000097:blood; D016022:Case-Control Studies; D056486:Chemical and Drug Induced Liver Injury / Q000150:complications; D002779:Cholestasis / Q000188:drug therapy* / Q000209:etiology; D004311:Double-Blind Method; D006525:Hepatitis, Viral, Human / Q000150:complications; D006801:Humans; D008104:Liver Cirrhosis, Alcoholic / Q000150:complications; D008111:Liver Function Tests; D008875:Middle Aged; D012633:Secretin / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D012633:Secretin; D001663:Bilirubin